TipRanks
Go Ultimate55% OFF

Lynn Seely Insider Profile

11 Followers

Lynn Seely, President & CEO, Director at Lyell Immunopharma, holds 63.90K shares in Lyell Immunopharma (Ticker: LYEL), holds 0.00 shares in Blueprint Medicines (Ticker: BPMC), holds 1.89M shares in Myovant Sciences (Ticker: MYOV). Most recently, Lynn Seely Sold ― shares of Lyell Immunopharma on Aug 25, 2026 for an estimated value of $149.01K.

Lynn Seely's Trading History

LYEL
Lyell Immunopharma
Aug 25, 2026President & CEO, DirectorInformative Sell149.01K$705.44K
BPMC
Blueprint Medicines
Jul 21, 2025―Uninformative Sell―$0.00
MYOV
Myovant Sciences
Apr 07, 2020―Uninformative Buy―$50.99M
MDVN
Medivation
Feb 10, 2015―Uninformative Buy―$7.81M
ABCL
AbCellera Biologics
―Director――

You May Also Like

Lynn Seely insider profile FAQ

What is the percentage of profitable transactions made by Lynn Seely?
The percentage of profitable transactions made by Lynn Seely is 70%.
What is the average return per transaction made by Lynn Seely?
The average return per transaction made by Lynn Seely is 15.30%.
What stocks does Lynn Seely hold?
Lynn Seely holds: LYEL, MDVN, BPMC, MYOV, ABCL stocks.
What was Lynn Seely’s latest transaction?
Lynn Seely’s latest transaction was an Informative Sell of $149.01K.
What was Lynn Seely's most profitable transaction?
Lynn Seely’s most profitable transaction was an Informative Sell of LYEL stock on February 12, 2026. The return on the trade was 56.50%.
What is Lynn Seely's role in Lyell Immunopharma?
Lynn Seely's role in Lyell Immunopharma is President & CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.